The mechanism(s) by which loss-of-function mutations in GATA2 and/or reduced GATA2 levels promote myeloid malignancies remains unclear, but the finding has generated interest in targeting GATA2 for the prognosis or treatment of hematologic disorders. Here, GATA2 is linked to myeloid neoplasm.